SI2968477T1 - Polipeptidne formulacije faktorja VIII - Google Patents

Polipeptidne formulacije faktorja VIII

Info

Publication number
SI2968477T1
SI2968477T1 SI201431514T SI201431514T SI2968477T1 SI 2968477 T1 SI2968477 T1 SI 2968477T1 SI 201431514 T SI201431514 T SI 201431514T SI 201431514 T SI201431514 T SI 201431514T SI 2968477 T1 SI2968477 T1 SI 2968477T1
Authority
SI
Slovenia
Prior art keywords
factor viii
viii polypeptide
polypeptide formulations
formulations
factor
Prior art date
Application number
SI201431514T
Other languages
English (en)
Inventor
Kevin Maloney
Ahmad Abdul-Fattah
Daniel Gage
Original Assignee
Bioverativ Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50771579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2968477(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioverativ Therapeutics Inc. filed Critical Bioverativ Therapeutics Inc.
Publication of SI2968477T1 publication Critical patent/SI2968477T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SI201431514T 2013-03-15 2014-03-14 Polipeptidne formulacije faktorja VIII SI2968477T1 (sl)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201361800293P 2013-03-15 2013-03-15
US201361817085P 2013-04-29 2013-04-29
US201361829884P 2013-05-31 2013-05-31
US201361839477P 2013-06-26 2013-06-26
US201361863860P 2013-08-08 2013-08-08
US201361876927P 2013-09-12 2013-09-12
US201361879955P 2013-09-19 2013-09-19
US201361897742P 2013-10-30 2013-10-30
EP14725816.4A EP2968477B1 (en) 2013-03-15 2014-03-14 Factor viii polypeptide formulations
PCT/US2014/029354 WO2014144795A1 (en) 2013-03-15 2014-03-14 Factor viii polypeptide formulations

Publications (1)

Publication Number Publication Date
SI2968477T1 true SI2968477T1 (sl) 2020-04-30

Family

ID=50771579

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201431514T SI2968477T1 (sl) 2013-03-15 2014-03-14 Polipeptidne formulacije faktorja VIII

Country Status (21)

Country Link
US (3) US9623088B2 (sl)
EP (3) EP2968477B1 (sl)
JP (5) JP6330026B2 (sl)
AU (3) AU2014228506A1 (sl)
CA (1) CA2899737A1 (sl)
CL (1) CL2015002720A1 (sl)
DK (1) DK2968477T3 (sl)
EA (2) EA201890671A1 (sl)
ES (2) ES2926798T3 (sl)
HK (1) HK1220617A1 (sl)
HU (1) HUE047933T2 (sl)
LT (1) LT2968477T (sl)
PH (2) PH12015501801B1 (sl)
PL (2) PL2968477T3 (sl)
PT (2) PT2968477T (sl)
RS (1) RS60003B1 (sl)
SG (2) SG10201805207QA (sl)
SI (1) SI2968477T1 (sl)
TW (2) TWI629993B (sl)
UY (1) UY35462A (sl)
WO (1) WO2014144795A1 (sl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010325787B2 (en) * 2009-12-06 2016-05-12 Bioverativ Therapeutics Inc. Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
ES2926798T3 (es) * 2013-03-15 2022-10-28 Bioverativ Therapeutics Inc Formulaciones de polipéptido de factor VIII
CN107759696A (zh) 2016-08-19 2018-03-06 安源医药科技（上海）有限公司 人白介素7融合蛋白及其制备方法
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN110520149A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 诱导对凝血因子的免疫耐受性的方法
EP3548066A1 (en) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
JP7039308B2 (ja) * 2017-02-08 2022-03-22 三洋化成工業株式会社 細胞培養用担体
US20210163986A1 (en) 2017-08-09 2021-06-03 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof
JP7370974B2 (ja) 2017-11-07 2023-10-30 ラニ セラピューティクス， エルエルシー 嚥下可能薬物送達デバイスを使用する腸管組織への送達のための凝固因子調製物
JP2021523878A (ja) 2018-05-18 2021-09-09 バイオベラティブ セラピューティクス インコーポレイテッド 血友病ａを処置する方法
US20200069817A1 (en) 2018-08-09 2020-03-05 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
CA3115535A1 (en) * 2018-10-23 2020-04-30 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor viii function
JP7501875B2 (ja) * 2019-02-28 2024-06-18 公立大学法人横浜市立大学 血液凝固および／または補体異常疾患の治療用組成物
JP2022531095A (ja) 2019-04-17 2022-07-06 コディアック バイオサイエンシーズ， インコーポレイテッド エキソソーム及びａａｖの組成物
CA3144630A1 (en) 2019-06-19 2020-12-24 Bioverativ Therapeutics Inc. Methods and compositions for treating hemophilia and low bone mineral density with factor viiifc protein
WO2023219379A1 (ko) * 2022-05-10 2023-11-16 주식회사 녹십자 혈장 단백질의 동결 건조를 위한 신규한 액상 제형물
KR20230159284A (ko) * 2022-05-10 2023-11-21 주식회사 녹십자 혈장 단백질에 대한 신규한 액상 제형물

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
CA1341174C (en) 1985-04-12 2001-01-30 John J. Toole Jr. Procoagulant proteins derived from factor viii: c
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
DE3785102T2 (de) 1986-01-03 1993-07-22 Genetics Inst Verfahren zur herstellung von faktor-viii:c-typ-proteinen.
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5543502A (en) 1986-06-24 1996-08-06 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
IE69026B1 (en) 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
ATE148171T1 (de) 1989-02-21 1997-02-15 Univ Washington Modifizierte formen von fortpflanzungshormonen
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
SG47099A1 (en) 1991-03-15 1998-03-20 Amgen Boulder Inc Pegylation of polypeptides
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
CA2124690C (en) * 1992-10-02 2007-09-11 Thomas Osterberg Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
DK2130554T3 (da) * 1999-02-22 2012-12-03 Univ Connecticut Albuminfrie faktor VIII-præparater
WO2001058957A2 (en) 2000-02-11 2001-08-16 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
ATE497783T1 (de) 2003-05-06 2011-02-15 Syntonix Pharmaceuticals Inc Gerinnungsfaktor vii-fc chimäre proteine zur behandlung von hämostatischen krankheiten
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
EP2298287B1 (en) * 2003-12-19 2018-04-11 Novo Nordisk Health Care AG Stabilised compositions of factor VII polypeptides
PT2371856T (pt) 2004-11-12 2022-08-12 Bayer Healthcare Llc Modificação de fviii direcionada a sítio
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
JP2009525986A (ja) * 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
CA2673459C (en) * 2006-12-22 2016-09-13 Stefan Schulte Modified coagulation factors with prolonged in vivo half-life
DK2369005T3 (da) 2007-06-21 2013-06-24 Univ Muenchen Tech Biologisk aktive proteiner med forøget stabilitet in vivo og/eller in vitro
US8239182B2 (en) 2007-12-04 2012-08-07 Spansion Llc Data transmission system-on-chip memory model based validation
JP5647899B2 (ja) 2008-01-08 2015-01-07 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化
CN102482340B (zh) 2009-04-06 2015-05-13 诺沃—诺迪斯克有限公司 因子viii蛋白向血小板的靶向递送
AU2010325787B2 (en) * 2009-12-06 2016-05-12 Bioverativ Therapeutics Inc. Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
EP3513804B1 (en) * 2011-07-08 2022-03-23 Bioverativ Therapeutics Inc. Factor viii chimeric and hybrid polypeptides, and methods of use thereof
CN103917554B (zh) * 2011-10-18 2017-03-08 杰特有限公司 用于改善重构后纯化的因子viii的稳定性的方法
WO2014026954A1 (en) * 2012-08-13 2014-02-20 Novo Nordisk A/S Liquid factor viii formulations
WO2014070953A1 (en) * 2012-10-30 2014-05-08 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide
ES2926798T3 (es) * 2013-03-15 2022-10-28 Bioverativ Therapeutics Inc Formulaciones de polipéptido de factor VIII

Also Published As

Publication number Publication date
JP2021181491A (ja) 2021-11-25
TWI629993B (zh) 2018-07-21
CL2015002720A1 (es) 2016-11-04
US20170281734A1 (en) 2017-10-05
EA201890671A1 (ru) 2019-01-31
UY35462A (es) 2014-10-31
PT3666283T (pt) 2022-09-13
US10786554B2 (en) 2020-09-29
EP2968477B1 (en) 2019-12-04
JP7240457B2 (ja) 2023-03-15
US20210069300A1 (en) 2021-03-11
HK1220617A1 (zh) 2017-05-12
PH12015501801A1 (en) 2015-11-09
US20140308280A1 (en) 2014-10-16
DK2968477T3 (da) 2020-03-09
HUE047933T2 (hu) 2020-05-28
JP2018123161A (ja) 2018-08-09
SG10201805207QA (en) 2018-07-30
AU2014228506A1 (en) 2015-08-13
PL2968477T3 (pl) 2020-06-15
TW201842930A (zh) 2018-12-16
CA2899737A1 (en) 2014-09-18
JP2020186268A (ja) 2020-11-19
JP6934994B2 (ja) 2021-09-15
EA201591439A1 (ru) 2016-03-31
EP3666283A1 (en) 2020-06-17
AU2019202656A1 (en) 2019-05-09
AU2019202656B2 (en) 2021-09-02
ES2776195T3 (es) 2020-07-29
AU2021277601A1 (en) 2021-12-23
ES2926798T3 (es) 2022-10-28
JP6330026B2 (ja) 2018-05-23
LT2968477T (lt) 2020-03-10
PT2968477T (pt) 2020-03-11
SG11201505924TA (en) 2015-09-29
TWI690325B (zh) 2020-04-11
PH12015501801B1 (en) 2015-11-09
TW201501722A (zh) 2015-01-16
EP3666283B1 (en) 2022-06-08
JP2023060146A (ja) 2023-04-27
JP2016516722A (ja) 2016-06-09
PH12019502452A1 (en) 2021-02-08
EA030357B1 (ru) 2018-07-31
PL3666283T3 (pl) 2022-10-03
EP2968477A1 (en) 2016-01-20
WO2014144795A1 (en) 2014-09-18
RS60003B1 (sr) 2020-04-30
EP4122487A1 (en) 2023-01-25
US9623088B2 (en) 2017-04-18

Similar Documents

Publication Publication Date Title
HK1220617A1 (zh) 因子 多肽調配物
EP3065716C0 (en) FORMULATIONS
HK1220697A1 (zh) 肽組合物
HK1220619A1 (zh) 因子 多肽調配物
HRP20180452T1 (hr) Peptidi
HK1213273A1 (zh) 重組因子 製劑
HK1220366A1 (zh) 蛋白製劑
HK1211596A1 (en) Peptide
HK1211595A1 (en) Peptide
GB201315130D0 (en) Peptides
GB201316660D0 (en) Peptides
GB201300381D0 (en) Peptides